Magali Haas
Chief Medical Officer Psilera
Dr. Haas is a physician-scientist and biotech executive with 25+ years of global leadership across nonprofit, academic, and industry sectors advancing brain health. She currently serves as Chief Medical Officer and Board Director at Psilera Inc., where she advances the development of next-generation neuroplastogens to treat multiple brain disorders. Dr. Haas is the Founder and Board Chair of Cohen Veterans Bioscience, a pioneering 501(c)(3) nonprofit biomedical and technology research organization she led as CEO for over a decade. Under her leadership, the organization raised and deployed over $200 million to advance brain health, leveraging high-performance computing and data analytics to develop predictive disease models integrating biomarker, biosensor, and phenotypic data, with a focus on PTSD and traumatic brain injury. Earlier in her career, Dr. Haas held senior bench-to-bedside leadership roles at Johnson & Johnson, spanning early- and late-stage neuroscience R&D, translational medicine, and diagnostics and spearheaded integrative solutions approaches. She serves on national and international advisory boards, including the National Research Advisory Council to the U.S. Secretary of Veterans Affairs. Dr. Haas earned her MD and PhD in neuroscience from Albert Einstein College of Medicine.
Seminars
- Examining the evidence linking psychedelic induced synaptic and dendritic remodeling with changes in mood, cognition and emotional processing
- Exploring whether neuroplasticity is a mechanistic driver of efficacy or a downstream accompaniment to broader network level changes
- Comparing plasticity linked biomarkers, such as EEG signatures, sleep architecture shifts and neurotrophic factor changes, to determine which most reliably map onto clinical response
- Debating how much neuroplasticity is necessary, sufficient or even predictive for therapeutic benefit across different psychedelic and non psychedelic compounds
- Considering maladaptive behaviors underpinned by neuroplasticity in the brain
- How might we treat “neuroplastogens” differently: as a separate class
